0001415889-23-005412.txt : 20230324
0001415889-23-005412.hdr.sgml : 20230324
20230324210946
ACCESSION NUMBER: 0001415889-23-005412
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230322
FILED AS OF DATE: 20230324
DATE AS OF CHANGE: 20230324
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burns Thomas William
CENTRAL INDEX KEY: 0001644557
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37463
FILM NUMBER: 23761275
MAIL ADDRESS:
STREET 1: C/O GLAUKOS CORPORATION,
STREET 2: 26051 MERIT CIRCLE, SUITE 103
CITY: LAGUNA HILLS
STATE: CA
ZIP: 92653
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GLAUKOS Corp
CENTRAL INDEX KEY: 0001192448
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 229 AVENIDA FABRICANTE
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92672
BUSINESS PHONE: 949-367-9600
MAIL ADDRESS:
STREET 1: 229 AVENIDA FABRICANTE
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92672
FORMER COMPANY:
FORMER CONFORMED NAME: GLAUKOS CORP
DATE OF NAME CHANGE: 20020925
4
1
form4-03252023_010339.xml
X0407
4
2023-03-22
0001192448
GLAUKOS Corp
GKOS
0001644557
Burns Thomas William
C/O GLAUKOS CORPORATION
ONE GLAUKOS WAY
ALISO VIEJO
CA
92656
true
true
false
false
CHAIRMAN & CEO
0
Common Stock
2023-03-22
4
A
0
7294
0
A
679595
D
Stock Option (Right to Buy)
48.46
2023-03-22
4
A
0
110254
0
A
2033-03-22
Common Stock
110254
110254
D
Stock Option (Right to Buy)
60.78
2023-03-22
4
A
0
7258
0
A
2023-04-03
2032-03-24
Common Stock
7258
7258
D
Stock Option (Right to Buy)
55.18
2023-03-22
4
A
0
14727
0
A
2032-03-24
Common Stock
14727
14727
D
Represents shares of common stock underlying a portion of an award of restricted stock units previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on March 22, 2023 that certain of the operational targets had been achieved. The number of shares of common stock reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets. 50% of the number of shares of common stock reported herein will vest and be delivered in April 2023, and the remaining 50% will vest and be delivered in January 2024.
Includes 67,282 restricted stock units that have not yet vested or been delivered to the Reporting Person.
These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.
Represents an option to purchase shares of common stock previously granted by the Issuer on April 1, 2022 pursuant to the Reporting Person's election to receive a portion of his annual bonus for 2022 in the form of stock options rather than cash (the "Bonus Election"). The Issuer's Board of Directors determined on March 22, 2023 the annual bonus payable to the Reporting Person pursuant to the Issuer's 2022 executive bonus plan and the number of shares of common stock subject to the stock option earned by the Reporting Person in accordance with the Bonus Election, subject to continued employment through the vesting date. The option to purchase common stock will vest on April 3, 2023.
Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating & Governance Committee determined on March 22, 2023 that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.
50% of the portion of the option reported herein will vest and become exercisable in April 2023, and the remaining 50% will vest and become exercisable in January 2024.
Diana Scherer, Attorney-in-Fact
2023-03-24